New drug combo aims to boost cancer treatment

NCT ID NCT02379416

Completed Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 8 times

Summary

This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed to find the best dose and watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nilotinib and paclitaxel
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early phase 1 trial with only 47 participants, focused on safety and dosing. The combination may not shrink tumors or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

National Institutes of Health Clinical Center

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.